Next Generation Anti-infectives Biotech Platform
pitch_v1_importMaxwell has a "one drug for many bugs" deep learning-guided drug discovery platform technology which produces small molecules that can accurately mimic endogenous human peptides. The first human peptide being mimicked is LL-37 or "human cathelicidin antimicrobial peptide." LL-37 is used by the human innate immune system and all white blood cells to attack all known pathogens. Accurately and safely mimicking LL-37 could result in a super drug able to address many unmet medical needs, as well as current and future pandemics. The first biomimetic small molecule - MXB-22,510 - is on it's way to the FDA for human trials for a polymicrobial infection of sinus, called Chronic Rhinosinusitis, in Q1 2024. Dr Edward Rudnic, PhD, is a registered pharmacist - is the former US Head of R&D for Shire Pharmaceuticals, recently acquired by Takeda for $65 billion - and has successfully taken over 80 molecules through the FDA and into commercialization. Examples are Adderall XR, Carbatrol, Claritin, and other multi-billion dollar blockbusters.
See something off about this company?
Many viruses, bacteria and fungi are currently impossible to treat, especially when many of the bugs infect a patient all at once (called a polymicrobial infection). These pathogens drive some of the largest unmet medical needs like asthma, cystic fibrosis, post viral syndromes like Epstein Barr, Long COVID, fungal brain infections, dementias, deadly hospital acquired fungal and bacterial illness, and chronic sinus infections which are suffered by 12% of the population. Maxwell has selected a nasal spray application of MXB-22,510 to target chronic sinus infections are the first application of the biomimetic technology and has received highly encouraging written feedback from the FDA.
